HF50

DRUG2 trials

Sponsors

HighField Biopharmaceuticals Corporation

Conditions

Advanced Solid Tumors

Early Phase 1

HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

RecruitingNCT06822998

HighField Biopharmaceuticals CorporationAdvanced Solid Tumors

Start: 2025-06-11End: 2026-06-01Target: 10Updated: 2025-08-17

Phase 1

Safety and Activity of HF50 in Patients With Advanced Solid Tumors

Not yet recruitingNCT07601334

HighField Biopharmaceuticals CorporationAdvanced Solid Tumors

Start: 2026-06-30End: 2029-06-30Target: 45Updated: 2026-05-22